Clinical Trials Browser

Radiotherapy × Genitourinary × 90 days × Clear all

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07477626 2026-03-17

RADVAN

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT07245745 2026-03-16

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

Phase NA Recruiting

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT04075305 2026-03-05

MOMENTUM

BreastCNSGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Radiation Injuries, Rectal Neoplasms

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

Advanced Bladder Cancer

NCT03159676 2026-02-25

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

Prostatic Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

Wilms Tumor

NCT06037863 2026-02-23

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Phase NA Active not recruiting

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT04983095 2026-02-17

METRO

Phase NA Recruiting

Prostate Cancer Metastatic

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Phase EARLY_PHASE1 Recruiting

Prostatic Neoplasms

NCT05320406 2026-02-12

REVELUTION

Phase 2 Active not recruiting

94 enrolled 13 charts

Prostatic Neoplasms

NCT01517451 2026-02-11

Radiation and Androgen Ablation for Prostate Cancer

Phase 1/2 Completed

45 enrolled 11 charts

Adenocarcinoma of the Prostate

NCT06834152 2026-02-09

X-SMILE

Adenocarcinoma, Prostatic Hyperplasia, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT04879940 2026-02-05

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Phase 2 Recruiting

Prostatic Hyperplasia, Prostatic Neoplasms

NCT07202247 2026-02-04

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Phase 2 Recruiting

Prostatic Neoplasms

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

Phase 2 Recruiting

Prostatic Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03543189 2026-01-29

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Phase 1/2 Active not recruiting

Prostatic Diseases, Prostatic Neoplasms

NCT07364071 2026-01-27

SENTRY

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT06391034 2026-01-07

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Carcinoma, Transitional Cell

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms